Article Text

other Versions

PDF
NICE Guidelines for the use of drug-eluting stents: how do we establish worth?
  1. Mark A de Belder (mark.debelder{at}stees.nhs.uk)
  1. The James Cook University Hospital, Middlesbrough, United Kingdom

    Abstract

    The introduction of new healthcare technologies requires an appropriate discourse between clinicians who identify problems to be overcome and industrial partners that provide potential solutions. New products go through a tight regulatory process before they can be widely used. Although this process is somewhat different for medical devices compared with drugs, the principles are the same: demonstration of proof of principle and safety, and identification of patients most likely to benefit. However, their use nowadays depends as much on a demonstration of cost-effectiveness as on clinical effectiveness. Cost-effectiveness analysis requires quantification of both clinical effect and overall costs of different treatments.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles